Metformin, Exenatide, and Glargine Insulin in Combination for Treatment of Patients With Type 2 Diabetes.

Trial Profile

Metformin, Exenatide, and Glargine Insulin in Combination for Treatment of Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2013

At a glance

  • Drugs Exenatide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms MEXELIN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2012 Actual patient number added 40 according to ClinicalTrials.gov.
    • 12 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top